Müller, Thomas R.
Technical University of Munich
4 papers on CoChatORCID 0000-0001-5331-5522
Most cited papers
- Verified
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology
Thyroid Cancer Diagnosis and TreatmentRenal cell carcinoma treatment
Cited by 550
- Verified
Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function
Schober, K., Müller, T. R., Gökmen, F., Grassmann, S., Effenberger, M., Poltorak, M., Stemberger, C., Schumann, K., Roth, T. L., Marson, A., et al. (2019) · Nature Biomedical Engineering
CRISPR and Genetic EngineeringCAR-T cell therapy research
Cited by 178
- Verified
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., et al. (2013) · Annals of Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 104
- Verified
Orthotopic T-cell receptor replacement in primary human T cells using CRISPR-Cas9-mediated homology-directed repair
Moosmann, C., Müller, T. R., Busch, D. H., & Schober, K. (2022) · STAR Protocols
CRISPR and Genetic EngineeringCAR-T cell therapy research
Cited by 24
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free